Management of secondary central nervous system lymphoma

Affiliations

¹ Department of Haematology, University College London Hospitals NHS Trust, London, UK.
² Department of Haematology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.
³ Department of Haematology, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, UK.
⁴ Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
⁵ The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool University Hospitals NHS Trust, Liverpool, UK.
⁶ Haematology and Transplant Unit, The Christie NHS Foundation Trust, Manchester, UK.
⁷ Department of Haematology, Barking Havering and Redbridge University Hospital NHS Trust, Romford, UK.
⁸ Department of Haematology, Beatson West of Scotland Cancer Centre, Glasgow, UK.
⁹ Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.

Kate Cwynarski et al. Br J Haematol. 2023 Jan.

. 2023 Jan;200(2):160-169.

doi: 10.1111/bjh.18539. Epub 2022 Nov 21.

¹ Department of Haematology, University College London Hospitals NHS Trust, London, UK.
² Department of Haematology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.
³ Department of Haematology, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, UK.
⁴ Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
⁵ The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool University Hospitals NHS Trust, Liverpool, UK.
⁶ Haematology and Transplant Unit, The Christie NHS Foundation Trust, Manchester, UK.
⁷ Department of Haematology, Barking Havering and Redbridge University Hospital NHS Trust, Romford, UK.
⁸ Department of Haematology, Beatson West of Scotland Cancer Centre, Glasgow, UK.
⁹ Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.

No abstract available

Keywords: CNS; CNS relapse; chemotherapy; lymphoma; non-Hodgkin lymphoma.

References

1. Ferreri AJ, Calimeri T, Conte GM, Cattaneo D, Fallanca F, Ponzoni M, et al. R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma. Blood. 2019;134(3):252-62.
1. Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217-e227.
1. Schorb E, Fox CP, Kasenda B, Linton K, Martinez-Calle N, Calimeri T, et al. Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system-an international study of feasibility and efficacy in routine clinical practice. Br J Haematol. 2020;189:879-87.
1. Montesinos-Rongen M, Godlewska E, Brunn A, Wiestler OD, Siebert R, Deckert M. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol. 2011;122(6):791-2.
1. Berghoff AS, Ricken G, Widhalm G, Rajky O, Hainfellner JA, Birner P, et al. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). Clin Neuropathol. 2014;33(1):42-9.